Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Bezafibrate1件: Bezafibrate1件: D01366 (Name: Bezafibrate)1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬7件: 20, 93, 94, 160, 296, 316, 324
2Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy2件: Bezafibrate,
Ursodeoxycholic acid		2件: D00734 ,
D01366 (Name: Bezafibrate)		2件: NR1H4,
PPARA 💬		11件: Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 94
3Bezafibrate (drug)1件: Bezafibrate1件: D01366 (Name: Bezafibrate)1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 316
4Bezafibrate (INN 3968)1件: Bezafibrate1件: D01366 (Name: Bezafibrate)1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 324
5Bezafibrate 200 MG1件: Bezafibrate1件: D01366 (Name: Bezafibrate)1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
6Bezafibrate 200 MG Oral Tablet1件: Bezafibrate1件: D01366 (Name: Bezafibrate)1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
7Bezafibrate 400 MG1件: Bezafibrate1件: D01366 (Name: Bezafibrate)1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
8Bezafibrate IR1件: Bezafibrate1件: D01366 (Name: Bezafibrate)1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
9Bezafibrate SR1件: Bezafibrate1件: D01366 (Name: Bezafibrate)1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
10Bezafibrate, Beza, BZF, Bezalip1件: Bezafibrate1件: D01366 (Name: Bezafibrate)1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
11Bezafibrate, Beza, BZF, Bezalip mono1件: Bezafibrate1件: D01366 (Name: Bezafibrate)1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93